Trial for in vitro screening of cytotoxic T lymphocyte induction with use of allogeneic dendritic cells for patients with pleural or peritoneal carcinomatosis

Trial for in vitro screening of cytotoxic T lymphocyte induction with use of allogeneic dendritic cells for patients with pleural or peritoneal carcinomatosis - In vitro screening of CTL induction by allogeneic dendritic cells for pleural or peritoneal carcinomatosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001016

Enrollment

100

Registered

2008-02-05

Start date

2008-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal or pleural carcinomatosis (carcinomas of the stomach, colorectum, biliary duct, pancreas, uterus, ovary, kidney, lung or malignant melanoma etc.) and malignant mesothelioma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have been already clinically or histologically diagnosed as primary or recurrent stomach, colorectal, biliary, pancreas, uterine, ovarian, renal, lung cancers or malignant melanoma etc, or malignant mesothelioma with pleural or peritoneal carcinomatosis. 2) Malignant cells (class V) are detected in ascites or pleural effusion by cytological test. 3) New chemotherapy or radiotherapy should not be started during the present study. 4) Adequate cardiac, hepatic, renal, respiratory, and bone marrow functions. 5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 6) Body weight is more than 45kg for male and 40kg for female. 7) Expected survival over 6 months. 8) Written informed consent must be obtained from patients and legally acceptable representatives.

Exclusion criteria

Exclusion criteria: 1) Active double cancer. 2) Exclude the patients who have serious illness or suspect to have serious illness. 3) Myocardial infarction or unstable angina, occurred within 6 months. 4) Psychosis. 5) Women during pregnancy or breast-feeding. 6) Previous history of severe drug-induced allergy. 7) Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial.

Design outcomes

Primary

Measure	Time frame
Induction rate of cancer-specific cytotoxic T lymphocyte (CTL) in vitro	—

Secondary

Measure	Time frame
Cytotoxic potency or cytokine production of the cancer-specific CTL	—

Countries

Japan

Contacts

Public ContactTakashi Kamigaki

Kobe University Hospital Division of Gastrointestinal Surgery

menekidc@med.kobe-u.ac.jp078-382-5925

Outcome results